Pipeline
Four programs. One gut-first strategy.
You need differentiated metabolic assets with a clear de-risking story. Each ApaisBio program is designed to act in the gut, and each moves forward only when it clears a gate.
Program descriptions reflect goals and design intent, not demonstrated results.
01 / Gated path
A gated path from discovery to a partner
Every step is a go/no-go decision. We plan to advance each program through preclinical de-risking and then license it to a pharmaceutical partner (see our model).
- 01Discover (in silico)
- 02Confirm (in vitro)
- 03Preclinical (in vivo)
- 04Partner and license
02 / The portfolio
Where each program stands today
- 01
An oral molecule designed to help people feel satisfied sooner and eat less, by engaging several connected appetite signals locally in the gut.
Preclinical (early in vivo) - 02
Metabolic tuning
Support healthier metabolism beyond the number on the scale, such as preserving lean mass and supporting healthy fat metabolism and energy balance.
Discovery (in silico) - 03
Gut inflammation
Calm inflammation locally in the gut lining while limiting exposure elsewhere in the body.
Discovery (in silico) - 04
Gut-brain axis
Tune the messages the gut sends to the brain about hunger and fullness, working from the gut side.
Discovery (in silico)
03 / Lead franchise
Gut-restricted polypharmacology for weight loss
Appetite isn't one switch, so our lead program isn't built around one. The molecule is designed to be taken by mouth, to stay in the gut, and to engage several connected signals that help you feel full. Our goal is weight loss that people can sustain, with fewer of the side effects that cause many to stop treatment.
Early signal
In an early acute study in lean mice, one oral dose was followed by about 40% lower 6-hour food intake versus controls.
Preclinical data Early mouse readout (preclinical) One small study in lean mice: food intake, activity, and body mass over 6 hours
Please read first. Early acute preclinical study in lean mice (n=4 dosed vs n=6 controls). Hypothesis-generating; not efficacy, not human data, not medical advice. Not yet peer reviewed.
The question was narrow: after one oral dose, do lean mice eat less once food returns after a fast? Food intake, body mass, and activity were tracked automatically in metabolic cages for 6 hours.
| Hour | Controls (n=6) | Dosed (n=4) |
|---|---|---|
| 1 h | 0.294 ± 0.082 | 0.181 ± 0.045 |
| 2 h | 0.380 ± 0.081 | 0.255 ± 0.056 |
| 3 h | 0.533 ± 0.133 | 0.355 ± 0.066 |
| 4 h | 0.705 ± 0.108 | 0.478 ± 0.078 |
| 5 h | 0.869 ± 0.155 | 0.551 ± 0.096 |
| 6 h | 1.075 ± 0.124 | 0.649 ± 0.065 |
At 6 h: 0.649 g vs 1.075 g cumulative intake, about 40% lower. All 4 dosed mice ate less than all 6 controls.
Mean ± SEM; shaded bands show SEM.
| Hour | Controls (n=6) | Dosed (n=4) |
|---|---|---|
| 0–1 h | 5.2 ± 0.5 | 4.9 ± 0.9 |
| 1–2 h | 2.1 ± 0.7 | 1.2 ± 0.5 |
| 2–3 h | 2.2 ± 0.5 | 0.9 ± 0.2 |
| 3–4 h | 2.4 ± 1.1 | 1.0 ± 0.4 |
| 4–5 h | 1.3 ± 0.4 | 1.3 ± 0.4 |
| 5–6 h | 3.4 ± 1.5 | 1.3 ± 0.7 |
First hour: 4.9 vs 5.2 m/h. Both groups showed the same burst of activity when food returned.
Mean ± SEM; first hour highlighted. Afterward, dosed mice moved less on average as they ate less (0–6 h mean 1.8 vs 2.8 m/h, not statistically resolved). Over the full multi-day run, activity showed no sustained separation.
Body mass
Body-mass regain after the fast trended lower in dosed mice (+0.57 g vs +1.14 g at 6 h). The difference was smaller than for intake and was not statistically resolved.
What this study does not show
It was not designed to show how the molecule works, whether the effect lasts, or whether it leads to weight loss. Two additional dosed mice with presumed capsule failures were excluded after the study; with them included, 6-hour intake did not differ between groups.
Next steps, each a go/no-go gate
- 01Acid stability
- 02Liability screens
- 03Diet-induced obesity study
Study reports are available to qualified partners under confidentiality and other agreements.
04 / Portfolio aim
Our aim is a portfolio, not a single product: programs that we hope could one day serve people across the spectrum, from modest, near-term goals to bariatric-level need, and that pharma partners can combine with, or offer alongside, existing therapies.
Want to look under the hood?
Study reports and program detail are shared with qualified partners under a confidentiality agreement.
Partnering and investment inquiries